Topical formulations comprising a steroid
US-2016361325-A1 · Dec 15, 2016 · US
Antimycotic pharmaceutical composition
US9050271B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9050271-B2 |
| Application number | US-201013258324-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 9, 2010 |
| Priority date | Apr 9, 2009 |
| Publication date | Jun 9, 2015 |
| Grant date | Jun 9, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition for external use, comprising: 1) luliconazole of the following general formula (1) and/or a salt thereof; 2) at least one kind selected from a higher alcohol which is in a liquid state at 1 atm and 25° C. and a diester of a dibasic acid, provided that a diester carbonate is excluded; and 3) 5 to 20% by mass with respect to a total amount of the pharmaceutical composition of at least one polyoxethylene alkyl ether selected fro…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K9/7015Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9050271B2 cover?
- In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other…
- Who is the assignee on this patent?
- Kobayashi Hirokazu, Kosugi Eiko, Kubota Nobuo, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K9/7015. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).